Periprocedural Anticoagulation Management of Patients With Venous Thromboembolism

摘要: Objective— Patients with venous thromboembolism (VTE) often require temporary warfarin interruption for an invasive procedure. The incidence of and bleeding related to periprocedural anticoagulation management such patients is unknown. Methods Results— In a protocol-driven, inception cohort design study, all VTE (n=775) referred (1997–2007) were followed-up estimate the 3-month cumulative bleeding. stratified by thrombus acuity (acute, <30 days; subacute, 31–90 or chronic ≥91 days). Decisions provide “bridging” low-molecular-weight heparin based on estimated risk. Low-molecular-weight was more administered in acute (87%) subacute (81%) compared (59%; P <0.001). (1.8%), major hemorrhage mortality (1.7%) low did not differ strategy. Active cancer only independent predictor thrombotic recurrence (HR, 4.86; 95% CI, 1.6–14.5; =0.005), 6.8; 2.1–21.7; =0.001), death 32.7; 4.3–251.2; =0.0008). Conclusion— Thromboembolism, bleeding, among whom temporarily interrupted procedure low. Cancer particular care given their propensity both clotting